News & Updates

Amiloride noninferior to spironolactone for resistant hypertension

05 Jun 2025

In the treatment of patients with resistant hypertension, amiloride is no better or worse than spironolactone at reducing home systolic blood pressure (SBP) levels, according to a study.

Amiloride noninferior to spironolactone for resistant hypertension

05 Jun 2025

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

04 Jun 2025

For older adults who received treatment with antipsychotics to manage delirium, medication discontinuation leads to better outcomes, including reduced risks of all-cause rehospitalization and mortality, compared with continued use, according to a study.

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

04 Jun 2025

Phase IIb study supports lorundrostat for treatment-resistant hypertension

04 Jun 2025 by

The phase IIb Advance-HTN trial shows the blood pressure (BP)-lowering effect of lorundrostat in patients with uncontrolled and treatment-resistant hypertension (HTN).

Phase IIb study supports lorundrostat for treatment-resistant hypertension

04 Jun 2025

Residual recurrence risk high after AF-related stroke

04 Jun 2025

Approximately one in six atrial fibrillation (AF) patients who sustained a stroke experiences another one within 5 years despite receiving modern preventive therapy, according to a systematic review and meta-analysis.

Residual recurrence risk high after AF-related stroke

04 Jun 2025

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025 by

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

03 Jun 2025 by

Updated results from the open-label, phase IIIb WAYFINDER study continue to support the oral corticosteroid (OCS)-sparing efficacy of tezepelumab in the treatment of patients with OCS-dependent severe asthma.

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

03 Jun 2025

No link between nicotinamide exposure and MACE

03 Jun 2025

Adults who are exposed to nicotinamide do not appear to be at increased risk of major cardiovascular events (MACE), according to a large retrospective cohort study.

No link between nicotinamide exposure and MACE

03 Jun 2025

Modified minocycline hydrochloride formulation works against papulopustular rosacea

02 Jun 2025

In the treatment of moderate-to-severe papulopustular rosacea (PPR), the low-dose modified formulation of minocycline hydrochloride, DFD-29, appears to have superior efficacy compared with both doxycycline and placebo, according to data from the phase III MVOR-1 and MVOR-2 studies.

Modified minocycline hydrochloride formulation works against papulopustular rosacea

02 Jun 2025

Add-on zilebesiran helps lower BP in uncontrolled hypertension

01 Jun 2025 by

The addition of a single subcutaneous dose of zilebesiran to background therapies appears to provide blood pressure (BP)-lowering benefit in patients with uncontrolled hypertension, according to the phase II KARDIA-2 study.

Add-on zilebesiran helps lower BP in uncontrolled hypertension

01 Jun 2025

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025 by

Cytisinicline’s efficacy and tolerability for smoking cessation has been validated in another large phase III trial conducted in the US, with both the 6- and 12-week treatments yielding positive benefits persisting through 24 weeks.

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

31 May 2025

News & Updates

Filter by Specialty:

Specialty:

Amiloride noninferior to spironolactone for resistant hypertension

Amiloride noninferior to spironolactone for resistant hypertension

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

Discontinuing antipsychotics for delirium lowers risks of rehospitalization, mortality

Phase IIb study supports lorundrostat for treatment-resistant hypertension

Phase IIb study supports lorundrostat for treatment-resistant hypertension

Residual recurrence risk high after AF-related stroke

Residual recurrence risk high after AF-related stroke

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

WAYFINDER updates boost tezepelumab role in OCS-dependent severe asthma

No link between nicotinamide exposure and MACE

No link between nicotinamide exposure and MACE

Modified minocycline hydrochloride formulation works against papulopustular rosacea

Modified minocycline hydrochloride formulation works against papulopustular rosacea

Add-on zilebesiran helps lower BP in uncontrolled hypertension

Add-on zilebesiran helps lower BP in uncontrolled hypertension

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit

Cytisinicline confirmed to be efficacious, well-tolerated in smokers set to quit